Rosenwald Career
It has been almost twenty years since Dr. Lindsay Rosenwald started his career in medicine and the biosciences, in those years he has become known as a man of great advancement in biotechnology. His work with the sciences of medicine has earned him honor, and rightly so. Since Dr. Rosenwald started his career he has formed over forty companies, biotechnical and pharmaceutical in nature and gathered almost a billion dollars for the resources needed to finance biotechnical companies that have shown great promise.
Dr. Lindsay Rosenwalld is of course best known for his being an investment banker and venture capitalist, but also as a hedge fund manager. His first company, has provided many smaller biotechnical companies with the needed resources to further their work and develop some of the most beneficial drugs being tested and used today. Dr. Rosenwald gives his backing to companies where he sees the most potential therefore he is being a good steward of finances while helping humanity.
Lindsay graduated from Abington High School in 1973 and went on to pursue his career in medicine at Pennsylvania State University. He was a member of the honor society for business school known as Beta Gamma Sigma while he attended. After graduating there he was awarded a Bachelors of Science in finance degree which was in 1977. Lindsay then decided to pursue his medical interests at Temple University School of Medicine. He graduated there with a medical degree in 1983.
Deciding to begin his medical career, Dr. Lindsay Rosenwald enrolled for an internship at Abington Hospital and following that moved into private practice until 1986. It was then that he made a move that would seem outlandish to some, he went to Wall Street to become an analyst as well as physician.
By 1991 Dr. Rosenwald had now formed his group, in which he also had his first company. They provide funding to companies in the biotechnology sector that are looking to develop treatment options that are breakthrough in nature,that includes helping with their start ups and research for development.
Related posts: